Moreover, somatic mutations in TP53 and MSH2 have been shown to act synergistically to promote tumour development (Toft et al, 2002), potentially bypassing p53 checkpoints and allowing increased genomic instability. This evidence concerns the gene MSH2 and neoplasm.